Article Details
Retrieved on: 2018-03-09 02:33:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Galectin Therapeutics, Inc. (GALT) has risen 62.09% since March 9, 2017 and is uptrending. It has outperformed by 45.39% the S&P500. <b>Benchmark Capital</b> Advisors holds 0.32% of its portfolio in Galectin Therapeutics, Inc. for 194,200 shares. Courage Capital Management Llc owns 130,000 shares or ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here